Sangamo BioSciences, Inc. (SGMO) Expected to Post Quarterly Sales of $6.79 Million
Wall Street brokerages expect Sangamo BioSciences, Inc. (NASDAQ:SGMO) to report sales of $6.79 million for the current quarter, Zacks reports. Three analysts have made estimates for Sangamo BioSciences’ earnings, with estimates ranging from $4.10 million to $10.40 million. Sangamo BioSciences reported sales of $3.70 million during the same quarter last year, which indicates a positive year over year growth rate of 83.5%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 2nd.
According to Zacks, analysts expect that Sangamo BioSciences will report full year sales of $6.79 million for the current year, with estimates ranging from $18.00 million to $85.60 million. For the next year, analysts anticipate that the business will report sales of $47.51 million per share, with estimates ranging from $16.33 million to $87.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Sangamo BioSciences.
Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. The firm had revenue of $3.40 million during the quarter, compared to analyst estimates of $4.14 million. Sangamo BioSciences had a negative return on equity of 50.76% and a negative net margin of 380.44%. The business’s revenue for the quarter was down 12.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.23) EPS.
SGMO has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Cowen and Company reissued a “buy” rating on shares of Sangamo BioSciences in a report on Wednesday, March 22nd. ValuEngine raised shares of Sangamo BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $17.00 target price on shares of Sangamo BioSciences in a report on Thursday, June 22nd. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 target price (down previously from $6.00) on shares of Sangamo BioSciences in a report on Tuesday, May 16th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Sangamo BioSciences presently has a consensus rating of “Hold” and an average target price of $8.50.
Sangamo BioSciences (NASDAQ SGMO) remained flat at $9.25 on Friday. The company’s stock had a trading volume of 961,351 shares. The firm’s 50-day moving average price is $7.82 and its 200-day moving average price is $4.99. Sangamo BioSciences has a 1-year low of $2.65 and a 1-year high of $9.65. The stock’s market cap is $665.44 million.
COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/07/sangamo-biosciences-inc-sgmo-expected-to-post-quarterly-sales-of-6-79-million-updated-updated-updated.html.
Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Sangamo BioSciences during the fourth quarter valued at approximately $179,000. A.R.T. Advisors LLC purchased a new stake in shares of Sangamo BioSciences during the fourth quarter valued at approximately $161,000. Tudor Investment Corp Et Al purchased a new stake in shares of Sangamo BioSciences during the fourth quarter valued at approximately $201,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Sangamo BioSciences by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Sangamo BioSciences by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 7,693 shares during the last quarter. Institutional investors own 59.23% of the company’s stock.
About Sangamo BioSciences
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related stocks with our FREE daily email newsletter.